Law360, New York (August 19, 2010, 7:23 PM ET) -- A federal judge has found that a Boehringer Ingelheim International GmbH patent was violated through Mylan Pharmaceuticals Inc.'s efforts to introduce a generic version of restless leg syndrome treatment Mirapex.
Judge Faith S. Hochberg of the U.S. District Court for the District of New Jersey on Wednesday signed a consent judgment in favor of Boehringer on its claims that Mylan’s abbreviated new drug application for generic 0.75 mg pramipexole dihydrochloride tablets infringed U.S. Patent Number 4,886,812.
The judgment enjoins Mylan from making and selling the proposed...
Mylan Violated Mirapex Patent, Judge Rules
To view the full article, take a free trial now.
